Johnson & Johnson’s blockbuster immunology drug Stelara is facing its first approved biosimilar in Europe, which is due to launch after the drug loses EU patent protec
A lawsuit in the US is accusing Johnson & Johnson of unlawfully delaying the onset of biosimilar competition to its immunology blockbuster Stelara beyond its US patent
AbbVie has built the case for its IL-23 inhibitor Skyrizi as a treatment for Crohn’s disease, saying its drug was more effective than Johnson & Johnson’s widely-used S
AstraZeneca has taken a look at the competition emerging in the market for inflammatory bowel disease (IBD) therapies, and decided to shelve a project that had advanced in
Johnson & Johnson posted a loss in the first three months of the year as it booked a massive $6.9 billion charge related to its recently-agreed proposal to settle clai
South Korea’s Hyundai Bioscience is preparing to start clinical trials of what it hopes could become the first antiviral treatment for dengue fever, a mosquito-borne viral
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.